Pliant Therapeutics, Inc. (NASDAQ:PLRX) Receives Average Recommendation of “Reduce” from Brokerages

Posted by on Jul 6th, 2026

Shares of Pliant Therapeutics, Inc. (NASDAQ:PLRX – Get Free Report) have received an average recommendation of “Reduce” from the five brokerages that are covering the company, Marketbeat.com reports. Two investment analysts have rated the stock with a sell rating, two have given a hold rating and one has assigned a buy rating to the company. The average twelve-month price target among brokerages that have issued ratings on the stock in the last year is $3.00.

A number of analysts have commented on the stock. Piper Sandler dropped their price target on shares of Pliant Therapeutics from $4.00 to $3.00 and set an “overweight” rating on the stock in a research report on Thursday, March 12th. Canaccord Genuity Group decreased their price objective on shares of Pliant Therapeutics from $4.00 to $3.00 and set a “hold” rating for the company in a report on Friday, March 13th. Wall Street Zen upgraded shares of Pliant Therapeutics from a “sell” rating to a “hold” rating in a research note on Tuesday, May 19th. Finally, Weiss Ratings reissued a “sell (e+)” rating on shares of Pliant Therapeutics in a report on Tuesday, April 21st.

Check Out Our Latest Report on Pliant Therapeutics

Institutional Trading of Pliant Therapeutics

Hedge funds and other institutional investors have recently modified their holdings of the company. ADAR1 Capital Management LLC lifted its holdings in shares of Pliant Therapeutics by 3,402.0% in the first quarter. ADAR1 Capital Management LLC now owns 2,585,126 shares of the company’s stock valued at $3,257,000 after buying an additional 2,511,307 shares during the period. Eversept Partners LP raised its position in Pliant Therapeutics by 5.9% in the first quarter. Eversept Partners LP now owns 891,425 shares of the company’s stock worth $1,123,000 after acquiring an additional 49,402 shares in the last quarter. Torno Capital LLC raised its position in Pliant Therapeutics by 9.4% in the first quarter. Torno Capital LLC now owns 350,000 shares of the company’s stock worth $441,000 after acquiring an additional 30,000 shares in the last quarter. Renaissance Technologies LLC lifted its holdings in Pliant Therapeutics by 77.2% in the 1st quarter. Renaissance Technologies LLC now owns 1,852,842 shares of the company’s stock valued at $2,335,000 after acquiring an additional 807,024 shares during the last quarter. Finally, Public Employees Retirement System of Ohio acquired a new stake in Pliant Therapeutics in the 1st quarter valued at about $36,000. Institutional investors own 97.30% of the company’s stock.

Pliant Therapeutics Stock Performance

NASDAQ:PLRX opened at $1.17 on Monday. Pliant Therapeutics has a 1 year low of $1.09 and a 1 year high of $1.95. The stock has a market cap of $72.45 million, a price-to-earnings ratio of -0.64 and a beta of 1.21. The business has a fifty day moving average of $1.18 and a 200-day moving average of $1.24.

Pliant Therapeutics (NASDAQ:PLRX – Get Free Report) last issued its quarterly earnings data on Monday, May 11th. The company reported ($0.32) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.36) by $0.04. On average, equities research analysts predict that Pliant Therapeutics will post -1.31 EPS for the current year.

About Pliant Therapeutics

(Get Free Report)

Pliant Therapeutics, Inc (NASDAQ: PLRX) is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for fibrotic diseases. Headquartered in Redwood City, California, Pliant applies a precision medicine approach to target integrin-mediated signaling pathways implicated in the development and progression of fibrosis across organ systems.

The company’s lead product candidate, PLN-74809, is an oral small molecule designed to inhibit both αvβ1 and αvβ6 integrins in patients with idiopathic pulmonary fibrosis (IPF) and primary sclerosing cholangitis (PSC).

Featured Articles

Analyst Recommendations for Pliant Therapeutics (NASDAQ:PLRX)

Receive News & Ratings for Pliant Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pliant Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.